Researchers found that metformin reduces the level of glucose and inhibits fatty acid synthesis in mice, resulting in significantly fewer and smaller liver tumors. The drug has been linked to reduced risk of liver cancer in patients with Type II diabetes and obesity.
A phase II study found metformin reduced fasting glucose, insulin levels and body mass index in men with prostate cancer. The medication also appeared to slow the growth rate of prostate cancer in a proportion of men.
Galeterone, a small-molecule oral drug, demonstrated limited side effects and reduced prostate-specific antigen expression in patients with castration-resistant prostate cancer. The drug's triple mechanism of action showed promise in blocking the growth of prostate cancer cells.
A Phase 1 study demonstrated galeterone's tolerability and efficacy in patients with castration-resistant prostate cancer, with minimal toxicities reported. The study showed significant reductions in tumor size and prostate-specific antigen levels in nearly half of the patients evaluated.
A recent study has found that low oxygen levels in tumors can predict cancer recurrence in men with intermediate-risk prostate cancer. The research, led by radiation oncologists at the Princess Margaret Hospital, suggests that these patients are more likely to develop cancer recurrence within a few years of completing treatment.
The European Respiratory Society and ECDC introduce new EU Standards for Tuberculosis Care to bridge gaps in TB case management. The guidelines include recommendations such as drug susceptibility testing and proper isolation protocols to combat multidrug-resistant TB cases.
Researchers identified pazopanib as a clinically meaningful treatment for refractory urothelial cancer. The study found that increases in interleukin-8 levels after treatment predicted a lack of tumor response, with 10% of patients experiencing long-term cure.
A combination of cixutumumab and temsirolimus shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, with two achieving complete responses. The study suggests that managing side effects is vital to maintaining the therapy and slowing disease progression.